Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...
The candlelighting ceremony at the World AIDS Day commemorative event. (Photo: PIA Samar) An early World AIDS Day observance ...
To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback